Refine
Has Fulltext
- yes (32) (remove)
Is part of the Bibliography
- yes (32)
Year of publication
Document Type
- Journal article (32) (remove)
Language
- English (32)
Keywords
- Medizin (3)
- liraglutide (3)
- obesity (3)
- Fn14 (2)
- MIZ1 (2)
- MYC (2)
- NFκB (2)
- Roux-en-Y gastric bypass surgery (2)
- TWEAK (2)
- agonistic antibodies (2)
- cell death (2)
- chemotherapy (2)
- colorectal cancer (2)
- gastric bypass (2)
- inflammation (2)
- peptide tyrosine tyrosine (PYY) (2)
- 5-fluorouracil (1)
- AAA (1)
- Barrett-Ösophagus (1)
- CD8+ T cells (1)
- CRC (1)
- CX5461 (1)
- Caco2 cells (1)
- ChIPseq (1)
- Chirurgie (1)
- Claudin2 (1)
- Dsg2 (1)
- FWGE (1)
- FcγR (1)
- GLP-1 (1)
- Germany (1)
- HUWE1 (1)
- Hesse (1)
- Krebs (1)
- MAPK signaling cascades (1)
- NAFLD (1)
- NASH (1)
- NFATc1 (1)
- Neolithic agriculture (1)
- PI-3-kinase (1)
- PYY3-36 (1)
- RNAPOL1 (1)
- RT-qPCT (1)
- RYGB (1)
- TKTL1 (1)
- TNF (1)
- TNF receptor superfamily (1)
- Y-gastric bypass (1)
- Zucker fatty fa/fa rats (1)
- adipose-derived stromal/stem cells (ASCs) (1)
- anti-tumor effects (1)
- autophagy (1)
- bariatric surgery (1)
- benzoquinone (1)
- biliopancreatic diversion (1)
- biological models (1)
- body weight (1)
- breast cancer (1)
- caco-2 cells (1)
- cadaver multiorgan preservation (1)
- cancer (1)
- cancer cell lines (1)
- cancer cells (1)
- carcinomas (1)
- chemistry (1)
- colon (1)
- colorectal carcinoma (1)
- cotransporter SGLT1 (1)
- cytostatic (1)
- cytotoxicity (1)
- desmosome (1)
- digestive system (1)
- drug discovery (1)
- duodenal jejunal bypass (1)
- energy homeostasis (1)
- enteroids (1)
- experimental archaeology (1)
- extracorporeal membrane oxygenation (1)
- fatty liver (1)
- food intake (1)
- glucagon like peptide-1 (1)
- glucose homeostasis (1)
- glucose starvation (1)
- gut barrier (1)
- gut hormones (1)
- heterologous (1)
- histologic diversity (1)
- hypothalamic gene expression (1)
- hypoxia (1)
- immunohistochemistry (1)
- implementation (1)
- inflammatory bowel disease (1)
- inflammatory cell model (1)
- intestinal barrier (1)
- intestinal epithelial barrier (1)
- intestinal glucose (1)
- intestinal organoids (1)
- ionizing radiation (1)
- ischemia (1)
- ischemic-stroke (1)
- ketogenic dients (1)
- ketogenic diet (1)
- ketone bodies (1)
- leptin system (1)
- metabolic profile (1)
- metabolism (1)
- metastasis (1)
- miRNA expression (1)
- mice (1)
- mild hypothermia (1)
- oxaliplatin (1)
- pathway analysis (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- pharmacology (1)
- popliteal aneurysm (1)
- post-mortem heart recovery (1)
- protein expression (1)
- quality indicators (1)
- quality of health care (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- reactive oxygen species (1)
- regenerative medicine (1)
- rehabilitation (1)
- ribosome (1)
- rygb (1)
- seahorse (1)
- secretion (1)
- slash-and-burn (1)
- small interferring RNA (1)
- stroke register (1)
- stroke unit care (1)
- study-group ADSR (1)
- temperate Europe (1)
- tight junction (1)
- translational research (1)
- transplantation (1)
- treatment (1)
- trophic factors (1)
- ubiquitination (1)
- β-Hydroxybutyrate (1)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (27)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Frauenklinik und Poliklinik (5)
- Institut für Anatomie und Zellbiologie (4)
- Medizinische Klinik und Poliklinik I (4)
- Pathologisches Institut (4)
- Comprehensive Cancer Center Mainfranken (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Molekulare Infektionsbiologie (2)
Sonstige beteiligte Institutionen
Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) in a rat model for early NAFLD. Methods: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY\(_{3-36}\) (0.1 mg/kg/day), liraglutide+PYY\(_{3-36}\), and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. Results: RYGB and liraglutide+PYY\(_{3-36}\) induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY\(_{3-36}\)- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. Conclusions: The combination therapy of liraglutide+PYY\(_{3-36}\) partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.
TNF-like weak inducer of apoptosis (TWEAK) and inhibition of protein synthesis with cycloheximide (CHX) sensitize for poly(I:C)-induced cell death. Notably, although CHX preferentially enhanced poly(I:C)-induced apoptosis, TWEAK enhanced primarily poly(I:C)-induced necroptosis. Both sensitizers of poly(I:C)-induced cell death, however, showed no major effect on proinflammatory poly(I:C) signaling. Analysis of a panel of HeLa-RIPK3 variants lacking TRADD, RIPK1, FADD, or caspase-8 expression revealed furthermore similarities and differences in the way how poly(I:C)/TWEAK, TNF, and TRAIL utilize these molecules for signaling. RIPK1 turned out to be essential for poly(I:C)/TWEAK-induced caspase-8-mediated apoptosis but was dispensable for this response in TNF and TRAIL signaling. TRADD-RIPK1-double deficiency differentially affected poly(I:C)-triggered gene induction but abrogated gene induction by TNF completely. FADD deficiency abrogated TRAIL- but not TNF- and poly(I:C)-induced necroptosis, whereas TRADD elicited protective activity against all three death inducers. A general protective activity against poly(I:C)-, TRAIL-, and TNF-induced cell death was also observed in FLIPL and FLIPS transfectrants.